Invitation to presentation of BICO’s Q1 results 2022
BICO’s interim report for the first quarter that ended on March 31, 2022 will be published in English and in Swedish on Wednesday May 18 2022 at 07:00 CEST.
Following the release of the report, combined presentation audiocasts and telephone conferences with the opportunity to ask questions will be held in English at 09:00 CEST and 16:00 CEST on the same day, with CEO Erik Gatenholm, CTO Hector Martinez, Interim CFO Mikael Engblom presenting the report.
The presentation audiocasts will be accessible via the following links:
Morning audiocast, at 09:00 CEST:
https://tv.streamfabriken.com/bico-q1-2022-am
To participate via telephone, please call any of the following numbers:
SE: +46 856 642 703
UK: +44 3333 009 034
US: +1 631 91 314 226
PIN for US: 46659360#
Afternoon audiocast, at 16:00 CEST:
https://tv.streamfabriken.com/bico-q1-2022-pm
To participate via telephone, please call any of the following numbers:
SE: + 46 850 558 352
UK: +44 3333 009 264
US: +1 6319 131 422
PIN for US: 36222967#
The presentation will also be available on the company’s website: https://bico.com/investors/financials/
For further information, please contact:
Åsa Hillsten, SVP Investor Relations, BICO Group AB
Phone: +46 70-081 81 17
Email: ash@bico.com
This information was submitted for publication, through the agency of the contact persons set out above, on May 11, 2022, at 07:00 (CEST).
About BICO
Founded in 2016, BICO (formerly CELLINK) is enabling the future of life-saving treatments by reducing the organ shortage and accelerating drug development by providing accessible life science solutions that combine biology and technology (bioconvergence). The company focuses on developing, manufacturing, selling, and supporting its life sciences equipment, consumables, and reagents for both manufacturing as well as research purposes. BICO has more than 25,000 products in the field, sales in more than 65 countries, delivers to all top 20 pharmaceutical companies, and have been cited in more than 10,000 scientific publications. BICO is listed on Nasdaq Stockholm under: BICO.